公开(公告)号：JPH10158291A

公开(公告)日：1998-06-16

申请号：JP32550897

申请日：1997-11-27

Applicant: HOECHST AG

Inventor： FRICK WENDELIN DR ,  MUELLER GUENTER DR

IPC: C07H15/207 ,  A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/715 ,  A61K31/716 ,  A61K38/28 ,  A61P3/08 ,  A61P3/10 ,  A61P5/00 ,  A61P5/48 ,  C07H3/04 ,  C07H3/06 ,  C07H11/04 ,  C07H15/203 ,  C08B37/00

Abstract: PROBLEM TO BE SOLVED: To obtain the new subject compound comprising a specific inositol glucan, having good serum stability and insulin-like activities against insulin resistant tissue, and useful for treatment, etc., of diabetes mellitus or noninsulin dependent diabetes mellitus. SOLUTION: The subject compound is a new inositol glucan of the formula A-Z-R [A is H-P(O) (OH), H-P(S) (OH), HO-P(S) (OH), (a 1-4C alkyl)-P(O) (OH), S(O)2 (OR ) (R is H or a 1-4C alkyl), R R N (R is same as R ), etc.; Z is 2-6 (substituted) saccharide groups; R is inositol, inositol phosphate, inositol thiophosphate, inositol cyclophosphate, inositol cyclothiophosphate, etc.]. The compound has in-vitro insulin-like activities, good serum stability and insulin-like activities against insulin resistant tissue and is useful for treatment, etc., of diabetes mellitus or noninsulin dependent diabetes mellitus.

公开(公告)号：BR9706041A

公开(公告)日：1999-11-23

申请号：BR9706041

申请日：1997-11-27

Applicant: HOECHST AG

Inventor： FRICK WENDELIN DR ,  MUELLER GUENTER DR

IPC: C07H15/207 ,  A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/715 ,  A61K31/716 ,  A61K38/28 ,  A61P3/08 ,  A61P3/10 ,  A61P5/00 ,  A61P5/48 ,  C07H3/04 ,  C07H3/06 ,  C07H11/04 ,  C07H15/203 ,  C08B37/00 ,  C07H13/00

Abstract: Inositol glycan derivatives of formula (I), their salts and stereoisomeric forms, are new: A-Z-R (I) A = HP(=O)(OH), HP(=S)(OH), HOP(=S)(OH), HSP(=S)(OH), (1-4C alkyl)P(=O)(OH), (1-4C alkyl)P(=S)(OH), SO2ORl, S(=O)OR1, NH2CO, NR1R2, R1R2NCONH, R1OSO2NH, (1-4C alkyl)SO2, (1-4C alkyl)S(=O) or R1S; R1, R2 = H or 1-4C alkyl; Z = 2-6 sugar residues (optionally substituted by up to 6 Me, sugar residue, di-sugar residue, SO2OH, CONR1R2, CO(1-4C alkyl), P(=O)(H)OH, P(=O)(OH)2, P(=S)(H)OH, P(=S)(OH)2, P(=S)(SH)(OH), P(=O)(OH)OCH2CH2NR1R2), or the glycosidic bridge between the 2-6 sugar residues may be 1-6 fold replaced by CH2 or S; R = inositol, inositol phosphate, inositol thiophosphate, inositol cyclo-phosphate, inositol cyclo-thiophosphate (optionally substituted by 1-2 phosphate or thiophosphate, or single substitution by cyclo-phosphate or cyclo-thiophosphate), or inositol (where two neighbouring OH groups are replaced by CH2SO2NH).

公开(公告)号：DE19649350A1

公开(公告)日：1998-06-04

申请号：DE19649350

申请日：1996-11-28

Applicant: HOECHST AG

Inventor： FRICK WENDELIN DR ,  MUELLER GUENTER DR

IPC: C07H15/207 ,  A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/715 ,  A61K31/716 ,  A61K38/28 ,  A61P3/08 ,  A61P3/10 ,  A61P5/00 ,  A61P5/48 ,  C07H3/04 ,  C07H3/06 ,  C07H11/04 ,  C07H15/203 ,  C08B37/00 ,  C07H17/00 ,  C07H23/00 ,  A61K31/72 ,  A61K31/735

Abstract: Inositol glycan derivatives of formula (I), their salts and stereoisomeric forms, are new: A-Z-R (I) A = HP(=O)(OH), HP(=S)(OH), HOP(=S)(OH), HSP(=S)(OH), (1-4C alkyl)P(=O)(OH), (1-4C alkyl)P(=S)(OH), SO2ORl, S(=O)OR1, NH2CO, NR1R2, R1R2NCONH, R1OSO2NH, (1-4C alkyl)SO2, (1-4C alkyl)S(=O) or R1S; R1, R2 = H or 1-4C alkyl; Z = 2-6 sugar residues (optionally substituted by up to 6 Me, sugar residue, di-sugar residue, SO2OH, CONR1R2, CO(1-4C alkyl), P(=O)(H)OH, P(=O)(OH)2, P(=S)(H)OH, P(=S)(OH)2, P(=S)(SH)(OH), P(=O)(OH)OCH2CH2NR1R2), or the glycosidic bridge between the 2-6 sugar residues may be 1-6 fold replaced by CH2 or S; R = inositol, inositol phosphate, inositol thiophosphate, inositol cyclo-phosphate, inositol cyclo-thiophosphate (optionally substituted by 1-2 phosphate or thiophosphate, or single substitution by cyclo-phosphate or cyclo-thiophosphate), or inositol (where two neighbouring OH groups are replaced by CH2SO2NH).

公开(公告)号：AT184611T

公开(公告)日：1999-10-15

申请号：AT92119913

申请日：1992-11-23

Applicant: HOECHST AG

Inventor： FRICK WENDELIN DR ,  MUELLER GUENTER DR ,  MUELLNER STEFAN DR ,  BREIPOHL GERHARD DR

IPC: A61K38/28 ,  A61K38/00 ,  A61P3/08 ,  A61P3/10 ,  C07K5/06 ,  C07K5/065 ,  C07K5/08 ,  C07K5/087 ,  C07K5/093 ,  C07K5/097 ,  C07K7/06 ,  C07K7/08 ,  C07K9/00

Abstract: Peptides with insulin-like activity and the formula I where C is a hydrogen atom, amino-acid residue, substituted amino-acid residue or sugar residue, D is an amino-acid residue, phosphoamino-acid residue, sugar residue, covalent bond or hydroxyl radical, E is a hydrogen atom, hydroxyl radical, substituted sugar residues, substituted alkyldiamine or glycerol residue, R is (C1-C4)-alkyl, =O or -O-(C1-C4)-alkyl, R is a sulphur protective group, SO2, SO3, (C1-C3)-alkyl, O2 radical, O3 radical, or hydrogen atom, R or R is, independently of one another, hydrogen or methyl, and W is an integer 1 or 2, the preparation and use thereof for the treatment of diabetes mellitus or non-insulin-dependent diabetes are described.

公开(公告)号：BR9706041C1

公开(公告)日：2000-06-06

申请号：BR9706041

申请日：1997-11-27

Applicant: HOECHST AG

Inventor： FRICK WENDELIN DR ,  MUELLER GUENTER DR

IPC: C07H15/207 ,  A61K31/70 ,  A61K31/7028 ,  A61K31/7034 ,  A61K31/715 ,  A61K31/716 ,  A61K38/28 ,  A61P3/08 ,  A61P3/10 ,  A61P5/00 ,  A61P5/48 ,  C07H3/04 ,  C07H3/06 ,  C07H11/04 ,  C07H15/203 ,  C08B37/00 ,  C07H13/00

Abstract: Inositol glycan derivatives of formula (I), their salts and stereoisomeric forms, are new: A-Z-R (I) A = HP(=O)(OH), HP(=S)(OH), HOP(=S)(OH), HSP(=S)(OH), (1-4C alkyl)P(=O)(OH), (1-4C alkyl)P(=S)(OH), SO2ORl, S(=O)OR1, NH2CO, NR1R2, R1R2NCONH, R1OSO2NH, (1-4C alkyl)SO2, (1-4C alkyl)S(=O) or R1S; R1, R2 = H or 1-4C alkyl; Z = 2-6 sugar residues (optionally substituted by up to 6 Me, sugar residue, di-sugar residue, SO2OH, CONR1R2, CO(1-4C alkyl), P(=O)(H)OH, P(=O)(OH)2, P(=S)(H)OH, P(=S)(OH)2, P(=S)(SH)(OH), P(=O)(OH)OCH2CH2NR1R2), or the glycosidic bridge between the 2-6 sugar residues may be 1-6 fold replaced by CH2 or S; R = inositol, inositol phosphate, inositol thiophosphate, inositol cyclo-phosphate, inositol cyclo-thiophosphate (optionally substituted by 1-2 phosphate or thiophosphate, or single substitution by cyclo-phosphate or cyclo-thiophosphate), or inositol (where two neighbouring OH groups are replaced by CH2SO2NH).

公开(公告)号：DK0545198T3

公开(公告)日：2000-03-20

申请号：DK92119913

申请日：1992-11-23

Applicant: HOECHST AG

Inventor： MUELLNER STEFAN DR ,  FRICK WENDELIN DR ,  MUELLER GUENTER DR ,  BREIPOHL GERHARD DR

IPC: A61K38/28 ,  A61K38/00 ,  A61P3/08 ,  A61P3/10 ,  C07K5/06 ,  C07K5/065 ,  C07K5/08 ,  C07K5/087 ,  C07K5/093 ,  C07K5/097 ,  C07K7/06 ,  C07K7/08 ,  C07K9/00 ,  A61K37/02

Abstract: Peptides with insulin-like activity and the formula I where C is a hydrogen atom, amino-acid residue, substituted amino-acid residue or sugar residue, D is an amino-acid residue, phosphoamino-acid residue, sugar residue, covalent bond or hydroxyl radical, E is a hydrogen atom, hydroxyl radical, substituted sugar residues, substituted alkyldiamine or glycerol residue, R is (C1-C4)-alkyl, =O or -O-(C1-C4)-alkyl, R is a sulphur protective group, SO2, SO3, (C1-C3)-alkyl, O2 radical, O3 radical, or hydrogen atom, R or R is, independently of one another, hydrogen or methyl, and W is an integer 1 or 2, the preparation and use thereof for the treatment of diabetes mellitus or non-insulin-dependent diabetes are described.

公开(公告)号：ES2137937T3

公开(公告)日：2000-01-01

申请号：ES92119913

申请日：1992-11-23

Applicant: HOECHST AG

Inventor： FRICK WENDELIN DR ,  MULLER GUNTER DR ,  MULLNER STEFAN DR ,  BREIPOHL GERHARD DR

IPC: A61K38/00 ,  A61P3/08 ,  A61P3/10 ,  C07K5/06 ,  C07K5/065 ,  C07K5/08 ,  A61K38/28 ,  C07K5/087 ,  C07K5/093 ,  C07K5/097 ,  C07K7/06 ,  C07K7/08 ,  C07K9/00

Abstract: Peptides with insulin-like activity and the formula I where C is a hydrogen atom, amino-acid residue, substituted amino-acid residue or sugar residue, D is an amino-acid residue, phosphoamino-acid residue, sugar residue, covalent bond or hydroxyl radical, E is a hydrogen atom, hydroxyl radical, substituted sugar residues, substituted alkyldiamine or glycerol residue, R is (C1-C4)-alkyl, =O or -O-(C1-C4)-alkyl, R is a sulphur protective group, SO2, SO3, (C1-C3)-alkyl, O2 radical, O3 radical, or hydrogen atom, R or R is, independently of one another, hydrogen or methyl, and W is an integer 1 or 2, the preparation and use thereof for the treatment of diabetes mellitus or non-insulin-dependent diabetes are described.